Serum High-Density Lipoprotein Cholesterol Concentrations in Pancreatic Ductal Adenocarcinoma and Its Association With Histological Grade in a Chinese Population

Overview

Journal Cancer Control

Date 2025 Feb 10

PMID 39927839

Authors

Ying-Ying Cao

Xiao-Jing Lv

Hui Li

Li-Chao Qian

Hai-Peng Si

Yuan Li

Kai Guo

Shuai Ren

Zhong-Qiu Wang

Affiliations

Soon will be listed here.

Abstract

Background: Serum high-density lipoprotein cholesterol (HDL-c) may influence cancer development. However, its relationship with the histological grade of pancreatic ductal adenocarcinoma (PDAC) is not well understood. This study aims to explore the potential associations between serum HDL-c levels and different histological grades of PDAC.

Methods: This retrospective study included 181 patients with pathologically confirmed PDAC who underwent radical surgery. Clinical data, blood biochemical results, imaging features, and pathological details of the patients were collected, such as age, gender, diabetes, hypertension, tumor grade, tumor size and location, high-density lipoprotein (HDL-c), low-density lipoprotein (LDL), total cholesterol (TC), triglycerides (TG), carbohydrate antigen 19-9 (CA19-9), and carcinoembryonic antigen (CEA).

Results: Patients with high-grade PDAC had significantly lower HDL-c levels compared to those with low-grade PDAC across both training and validation cohorts ( < 0.05). Significant associations were found between HDL-c levels and high-grade PDAC in the training ( < 0.001) and validation ( = 0.044) groups. Moreover, HDL-c levels were inversely related to lymph node metastasis in the training ( = 0.001) and validation ( = 0.012) sets.

Conclusions: Lower HDL-c levels are associated with high-grade PDAC and lymph node metastasis, suggesting that HDL-c may play a protective role in the progression of PDAC.

References

Tao M, Luo J, Gu T, Yu X, Song Z, Jun Y . LPCAT1 reprogramming cholesterol metabolism promotes the progression of esophageal squamous cell carcinoma. Cell Death Dis. 2021; 12(9):845. PMC: 8438019. DOI: 10.1038/s41419-021-04132-6. View

Guo E, Chen L, Xie Q, Chen J, Tang Z, Wu Y . Serum HDL-C as a potential biomarker for nodal stages in gastric cancer. Ann Surg Oncol. 2007; 14(9):2528-34. DOI: 10.1245/s10434-007-9401-0. View

Huang B, Song B, Xu C . Cholesterol metabolism in cancer: mechanisms and therapeutic opportunities. Nat Metab. 2020; 2(2):132-141. DOI: 10.1038/s42255-020-0174-0. View

Wu J, Zhang C, Zhang G, Wang Y, Zhang Z, Su W . Association Between Pretreatment Serum Apolipoprotein A1 and Prognosis of Solid Tumors in Chinese Population: A Systematic Review and Meta-Analysis. Cell Physiol Biochem. 2018; 51(2):575-588. DOI: 10.1159/000495277. View

von Elm E, Altman D, Egger M, Pocock S, Gotzsche P, Vandenbroucke J . The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med. 2007; 147(8):573-7. DOI: 10.7326/0003-4819-147-8-200710160-00010. View

Nurmi A, Mustonen H, Parviainen H, Peltola K, Haglund C, Seppanen H . Neoadjuvant therapy offers longer survival than upfront surgery for poorly differentiated and higher stage pancreatic cancer. Acta Oncol. 2017; 57(6):799-806. DOI: 10.1080/0284186X.2017.1415458. View

Nam S, Jo J, Cho C . A population-based cohort study of longitudinal change of high-density lipoprotein cholesterol impact on gastrointestinal cancer risk. Nat Commun. 2024; 15(1):2923. PMC: 10994902. DOI: 10.1038/s41467-024-47193-9. View

Goh S, Gold G, Christophi C, Muralidharan V . Serum carbohydrate antigen 19-9 in pancreatic adenocarcinoma: a mini review for surgeons. ANZ J Surg. 2017; 87(12):987-992. DOI: 10.1111/ans.14131. View

Cantoria M, Boros L, Meuillet E . Contextual inhibition of fatty acid synthesis by metformin involves glucose-derived acetyl-CoA and cholesterol in pancreatic tumor cells. Metabolomics. 2014; 10(1):91-104. PMC: 3890070. DOI: 10.1007/s11306-013-0555-4. View

10.

Zhao Q, Wang Y, Huo T, Li F, Zhou L, Feng Y . Exploration of Risk Factors for Pancreatic Cancer and Development of a Clinical High-Risk Group Rating Scale. J Clin Med. 2023; 12(1). PMC: 9821400. DOI: 10.3390/jcm12010358. View

11.

Siegel R, Miller K, Wagle N, Jemal A . Cancer statistics, 2023. CA Cancer J Clin. 2023; 73(1):17-48. DOI: 10.3322/caac.21763. View

12.

Zhang Y, Zhu X, Liu D, Song J, Zhang H, Lu J . Pre-treatment DWI as a predictor of overall survival in locally advanced pancreatic cancer treated with Cyberknife radiotherapy and sequential S-1 therapy. Cancer Imaging. 2018; 18(1):6. PMC: 5824450. DOI: 10.1186/s40644-018-0139-7. View

13.

Chang N, Cui L, Luo Y, Chang Z, Yu B, Liu Z . Development and multicenter validation of a CT-based radiomics signature for discriminating histological grades of pancreatic ductal adenocarcinoma. Quant Imaging Med Surg. 2020; 10(3):692-702. PMC: 7136722. DOI: 10.21037/qims.2020.02.21. View

14.

Wang X, Wang Y, Wang M, Chen X, Cui W, Chen X . The association between serum lipid levels and histological type of breast cancer. Eur J Med Res. 2022; 27(1):154. PMC: 9389787. DOI: 10.1186/s40001-022-00784-y. View

15.

Pirro M, Ricciuti B, Rader D, Catapano A, Sahebkar A, Banach M . High density lipoprotein cholesterol and cancer: Marker or causative?. Prog Lipid Res. 2018; 71:54-69. DOI: 10.1016/j.plipres.2018.06.001. View

16.

Oberle R, Kuhrer K, Osterreicher T, Weber F, Steinbauer S, Udonta F . The HDL particle composition determines its antitumor activity in pancreatic cancer. Life Sci Alliance. 2022; 5(9). PMC: 9112193. DOI: 10.26508/lsa.202101317. View

17.

Wu Q, Chen G, Wu W, Zhou L, You L, Zhang T . Metabolic syndrome components and risk factors for pancreatic adenocarcinoma: a case-control study in China. Digestion. 2012; 86(4):294-301. DOI: 10.1159/000341397. View

18.

Abdelrahim M, Esmail A, Kasi A, Esnaola N, Xiu J, Baca Y . Comparative molecular profiling of pancreatic ductal adenocarcinoma of the head versus body and tail. NPJ Precis Oncol. 2024; 8(1):85. PMC: 10998911. DOI: 10.1038/s41698-024-00571-4. View

19.

Jafri H, Alsheikh-Ali A, Karas R . Baseline and on-treatment high-density lipoprotein cholesterol and the risk of cancer in randomized controlled trials of lipid-altering therapy. J Am Coll Cardiol. 2010; 55(25):2846-54. DOI: 10.1016/j.jacc.2009.12.069. View

20.

Haddy N, Sass C, Droesch S, Zaiou M, Siest G, Ponthieux A . IL-6, TNF-alpha and atherosclerosis risk indicators in a healthy family population: the STANISLAS cohort. Atherosclerosis. 2003; 170(2):277-83. DOI: 10.1016/s0021-9150(03)00287-9. View